title: Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
abstract: OBJECTIVE
  To determine the safety and efficacy of multiple cycles of dose-intensive, nonablative chemotherapy in women with poor-prognosis breast cancer.
  
  
  METHODS
  Women with stage II breast cancer and 10 or more involved nodes or four or more involved nodes and estrogen receptor-negative tumors and women with stage III disease received three cycles of epirubicin 200 mg/m2 and cyclophosphamide 4 g/m2, with progenitor cell and filgrastim support every 28 days (n = 79) or 21 days (n = 20). Patients were reviewed at least twice yearly thereafter. Twenty-six patients had bone marrow and apheresis collections assessed for the presence of micrometastatic tumor cells.
  
  
  RESULTS
  Ninety-nine women (median age, 43 years; range, 24 to 60 years) were treated. Ninety-two completed all three cycles of chemotherapy. The major toxicity was severe, reversible myelosuppression that was more prolonged with successive cycles, and this did not differ between patients given treatment every 28 days and those treated every 21 days. Febrile neutropenia occurred in 176 (61%) of 287 cycles. Severe mucositis (grade 3 or 4) occurred in 23% of cycles but tended to be short-lived and was reversible. The cardiac ejection fraction fell by a median of 4% during treatment, and three patients developed evidence of cardiac failure after chemotherapy. Two patients (2%) died of acute toxicity. Three of 26 patients had evidence of circulating micrometastatic tumor cells. The actuarial distant disease-free and overall survival rates at 60-month follow-up were 64% (95% confidence interval [CI], 53% to 75%) and 67% (95% CI, 56% to 78%), respectively.
  
  
  CONCLUSIONS
  Multiple cycles of dose-intensive, nonablative chemotherapy is a feasible and safe approach. Disease control and survival are similar to those in other studies of myeloablative chemotherapy in poor-prognosis breast cancer. The regimen is being evaluated in a randomized trial of the International Breast Cancer Study Group.
authors.affiliation: Centre for Developmental Cancer Therapeutics, Parkville, Victoria, Australia. basser@licre.ludwig.edu.au
authors.forename: R L
authors.initials: RL
authors.lastname: Basser
authors.forename: L B
authors.initials: LB
authors.lastname: To
authors.forename: J P
authors.initials: JP
authors.lastname: Collins
authors.forename: C G
authors.initials: CG
authors.lastname: Begley
authors.forename: D
authors.initials: D
authors.lastname: Keefe
authors.forename: J
authors.initials: J
authors.lastname: Cebon
authors.forename: J
authors.initials: J
authors.lastname: Bashford
authors.forename: S
authors.initials: S
authors.lastname: Durrant
authors.forename: J
authors.initials: J
authors.lastname: Szer
authors.forename: D
authors.initials: D
authors.lastname: Kotasek
authors.forename: C A
authors.initials: CA
authors.lastname: Juttner
authors.forename: I
authors.initials: I
authors.lastname: Russell
authors.forename: D W
authors.initials: DW
authors.lastname: Maher
authors.forename: I
authors.initials: I
authors.lastname: Olver
authors.forename: W P
authors.initials: WP
authors.lastname: Sheridan
authors.forename: R M
authors.initials: RM
authors.lastname: Fox
authors.forename: M D
authors.initials: MD
authors.lastname: Green
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D000069585:Filgrastim; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating; D011379:Prognosis; D011994:Recombinant Proteins; D015996:Survival Rate
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D003520:Cyclophosphamide; D000069585:Filgrastim